• CFO in the Know: Bright spots for biopharma IPOs, but COVID-19 still lurks

  By Ted Knutson • June 8, 2020

  The pandemic has helped the atmosphere for biopharma IPOs by changing the focus of drugs from the downside of their pricing to the benefits they offer of better diagnostics and potential cures. Read the full article ➔

• CFO in the Know: Are CFOs ready to go with the EU's medical device regulations?

  By Ed McCarthy • May 12, 2020

  Requiring fewer applications to submit for approval, the new process could ultimately cost companies less. Read the full article ➔

• CFO in the Know: Tapping working capital lines to finance modular construction

  By Kim Slowey • April 14, 2020

  Components are completed faster and with fewer mistakes when they're built in a factory. Here's how to get financing when most lenders say "no." Read the full article ➔

• CFO in the Know: Protecting capital in pre-revenue biopharmas

  By Robert Freedman • March 10, 2020

  Last year, bankruptcies multiplied among early-stage drug companies, putting a premium on CFO finance management ideas.  Read the full article ➔

• CFO in the Know: Getting acquired in a 'snack-eat-snack' market

  By Jane Thier • Feb. 11, 2020

  Small food companies often form in hopes of acquisition by giants like Hershey or Mondelez. How can CFOs best help their companies prepare for such large-scale acquisitions? Read the full article ➔

• CFO in the Know: The 3 most common forecasting errors retail CFOs make

  By Robert Freedman • Jan. 14, 2020

  Smart investment on the planning side can help retailers better align forecasts with actual sales. Read the full article ➔

• CFO in the Know: Lime, other dockless scooters face winding path to profitability

  By Robert Freedman • Dec. 10, 2019

  Strewing scooters across a city for people to ride is a viable business model if the industry can pass a cost test.  Read the full article ➔

• CFO in the Know: Does the beef against beef make financial sense?

  By Barbara Ballinger • Nov. 12, 2019

  As the holidays approach, plant-based protein companies are making a play for the dinner table. Read the full article ➔